LEI:
549300Q7EXQQH6KF7Z84
14 November
2024
RTW Biotech Opportunities
Ltd
Monthly Valuation Update and
Factsheet
-0.6% NAV movement for the
month
RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited
net asset value attributable to the ordinary shares of the Company
at the close of business on 31 October 2024 (the "NAV") was US$650.6 million, or US$1.94
per ordinary share, -0.6% from the previous month.
The monthly factsheet
is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
For
Further Information
|
RTW
Investments, LP
|
+44
20 7959 6361
|
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
Cadarn Capital (PR & Communications / Distribution &
IR Partner)
Lucy Clark (PR)
David Harris
(Distribution)
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
Lucy@cadarncapital.com
+44
73 6888 3211
david@cadarncapital.com
+44
20 7260 1000
|
|
Freddie Barnfield
|
|
|
Nathan Brown
|
|
|
Euan Brown
|
|
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW) is an investment fund focused on identifying transformative
assets with high growth potential across the biopharmaceutical and
medical technology sectors. Driven by a long-term approach to
support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and
technologies that can significantly improve patients' lives. RTW
Biotech Opportunities Ltd is managed by RTW Investments, LP, a
leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********